Ascentage Pharma News and Resources

Ascentage Pharma, a China-based biotechnology firm, raised $126 million in its US initial public offering (IPO), marking the first biotech IPO of 2025. The company sold 7,325,000 American Depositary Shares (ADS) at $17.25 each. Trading began on 24 January on